A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

Inclusion Criteria: * The patient has documented paroxysmal, persistent, or permanent non-valvular AF (i.e., the patient has not been diagnosed with rheumatic mitral valve disease). * LAA closure with the WATCHMAN device is planned * The patient fulfills the FDA indication for WATCHMAN LAA closure * The patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial * The patient is able and willing to return for required follow-up visits and examinations. * The patient is 18 years of age or older Exclusion Criteria: * Conditions other than atrial fibrillation that require anti-coagulation (e.g., a prosthetic heart valve) * Stroke within the previous 7 days * Hypersensitivity to edoxaban * Moderate or severe mitral stenosis * A need for aspirin at a dose of \>81 mg a day * A need for on-going treatment with dual antiplatelet therapy with aspirin and clopidogrel * A need for on-going treatment with ticagrelor or prasugrel * No LAA closure device implanted during procedure * Procedural complication of LAA closure (e.g., stroke, systemic embolism, bleeding, vascular complication \[e.g., groin hematoma \>10cm, AV fistula, or pseudoaneurysm), or serious pericardial effusion) * Planned surgery or invasive procedure within 6±2 weeks of enrollment